Finnish biotech Nightingale Health, which provides a comprehensive blood analysis service world-wide to universities and medical research institutions, has announced a pilot of its technology in the healthcare sector. The goal of the pilot, in partnership with Finnish health service provider Coronaria, is to verify that Nightingale’s service can be successfully applied within a healthcare setting.
Nightingale's blood test can replace many routine blood tests currently used in healthcare (e.g. glucose tests). Additionally, Nightingale’s service provides other blood biomarkers that can enhance disease risk prediction. In the long-term, Nightingale plans to provide better tools for clinicians, enabling preventive healthcare for chronic diseases, such as diabetes and cardiovascular disease.
"The only sustainable way to reduce the burden of chronic diseases is to invest in their prevention. The goal of this cooperative pilot with Coronaria is to prove Nightingale's technology's suitability for routine clinical use," said Nightingale Health's CEO Teemu Suna.
The pilot's cooperative partner Coronaria is one of Finland's largest providers of healthcare services.
"Coronaria aims to build a novel healthcare system in Finland that will benefit all of us, with patients receiving better care, personnel achieving more and society saving money. The emphasis in healthcare must be shifted to preventive and personalized care, especially for chronic disease treatments. We see Nightingale's blood analysis as an important tool to achieve this goal. As a result, we wanted to be the first to pilot the service in Finland", said Olli Karhi, member of the board of Cor Group.
Teemu Suna
CEO, CO-founder
Nightingale Health Oy
p. +358 40 196 1669
press@nightingalehealth.com
About Nightingale Health
Nightingale Health Ltd. is a Finnish biotech company, transforming healthcare and research through use of its innovative blood analysis platform. By providing comprehensive and cost-effective data on blood, Nightingale’s mission is to solve the world’s number one health problem - chronic diseases. Nightingale Health’s quality management system has been audited according to the EN ISO 13485 standard. In July 2017, Nightingale obtained CE marking for its blood biomarker analysis platform.
Further information about Nightingale Health can be found at: https://nightingalehealth.com
About Coronaria
Coronaria is one of Finland's largest providers of healthcare services. A Finnish company founded by medical doctors, aims to reform national healthcare through its high-quality care, rehabilitation and healthcare services. Coronaria prides itself on its commitment to meet needs of individuals, providing healthcare services in as close proximity to patients as possible. A large-scale supplier of primary care, specialized healthcare, service housing, homecare and rehabilitation services, Coronaria has 2500 employees and reported revenue approximately 100M euros in 2016.
Further information about Coronaria can be found at:
https://www.coronaria.fi/en/home/
